Mode
Text Size
Log in / Sign up
N/A Completed N=30

Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication

Deep Mycosis
Source: ClinicalTrials.gov NCT01680458 ↗
Enrolled (actual)
30
Serious AEs
7.4%
Results posted
Dec 2015
Primary outcomePrimary: Number of Participants With Treatment-Related Adverse Events — 1 Participants

Summary

To collect the efficacy and safety information of fluconazole on infant subjects related to their appropriate use in daily practice.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Treatment-Related Adverse Events
1
PRIMARY
Number of Participants With Treatment-Related Serious Adverse Events
PRIMARY
Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
SECONDARY
Clinical Efficacy Rate
100
SECONDARY
Fungi Eradication Rate
SECONDARY
Onset Rate of Deep Mycosis

Eligibility Criteria

Inclusion Criteria

  • Male or Female under age of seven patients who are prescribed fluconazole (Diflucan) for antifungal treatment or prophylaxis administration.

Exclusion Criteria

  • Subject of seven years or more who have been prescribed fluconazole.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01680458). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search